Skip to content
Parakho

Bharat Parenterals Ltd

NSE BPLPHARMABSE 541096bplindia.in

Statement of profit and loss

Parakho has not ingested a filed result for this company on a consolidated basis. When the company files one with the exchange, it appears here automatically.

Earnings call

Q4 FY26

Bharat Parenterals reported consolidated FY26 revenue of INR345.4 crores, roughly flat year-on-year, with consolidated EBITDA rising to INR15.8 crores from INR2.7 crores, driven mainly by a narrowing of losses at subsidiary Innoxel Lifesciences. Standalone BPL revenue declined about 23% due to deferred export tenders, exit from low-margin business, and production line upgrades, while Varenyam Healthcare turned profitable with 13.7% revenue growth and Innoxel grew revenue 174.1% on licensing and milestone income. Management issued FY27 guidance across its three operating businesses and described FY26 as a transition year ahead of an expected commercial inflection.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 39 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 24 Aug 2026.